Dermata Therapeutics(DRMA) - 2025 Q1 - Quarterly Results

Filing Information This section details the registrant's identification, securities listing, and emerging growth company status Registrant Details This section provides Dermata Therapeutics, Inc.'s core identification details, including incorporation state, address, and contact information - Registrant: Dermata Therapeutics, Inc.[2] - Jurisdiction of Incorporation: Delaware[2] - Principal Executive Offices: 3525 Del Mar Heights Rd., 322, San Diego, CA 92130[2] Securities Information The company's common stock and warrants are registered on The Nasdaq Capital Market, indicating their public trading status Securities Listing | Title of Each Class: | Trading Symbol | Name of Each Exchange on which Registered | | :--- | :--- | :--- | | Common Stock, par value $0.0001 per share | DRMA | The Nasdaq Capital Market | | Warrants, exercisable for one share of Common Stock | DRMAW | The Nasdaq Capital Market | Emerging Growth Company Status Dermata Therapeutics, Inc. identifies as an emerging growth company and has elected not to use the extended transition period for new or revised financial accounting standards - The registrant is an emerging growth company[4] - The registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards[4] Item 2.02. Results of Operations and Financial Condition Dermata Therapeutics, Inc. disclosed Q1 2025 financial results via a May 14, 2025 press release, furnished but not filed, and exempt from Section 18 liabilities - On May 14, 2025, Dermata Therapeutics, Inc. issued a press release disclosing certain information regarding its results of operations for the quarter ended March 31, 2025[5] - A copy of the press release is furnished under Item 2.02 as Exhibit 99.1[5] - The information included in this Item 2.02 and Exhibit 99.1 shall not be deemed 'filed' for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934[6] Item 7.01. Regulation FD Disclosure This item cross-references Item 2.02, indicating that the information disclosed under Item 2.02 also satisfies the requirements for Regulation FD disclosure - This item refers to 'Item 2.02 Results of Operations and Financial Condition' above[7] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, which include the press release detailing Q1 2025 financial results and the interactive data file for the cover page Exhibits | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release, dated May 14, 2025, issued by Dermata Therapeutics, Inc. entitled "Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results." | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | Signature The report is duly signed on behalf of Dermata Therapeutics, Inc. by Gerald T. Proehl, its Chief Executive Officer, on May 14, 2025, affirming compliance with the Securities Exchange Act of 1934 - The report was signed by Gerald T. Proehl, Chief Executive Officer of DERMATA THERAPEUTICS, INC.[12] - The report was dated May 14, 2025[12]